CRISPR Therapeutics (NASDAQ:CRSP) Sees Unusually-High Trading Volume - Here's What Happened

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) saw strong trading volume on Monday . 3,089,526 shares traded hands during mid-day trading, an increase of 24% from the previous session's volume of 2,501,638 shares.The stock last traded at $68.40 and had previously closed at $65.13.

Analyst Ratings Changes

Several analysts recently commented on the company. JMP Securities reiterated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Needham & Company LLC reissued a "buy" rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, July 8th. Piper Sandler restated an "overweight" rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Chardan Capital reiterated a "buy" rating and set a $82.00 target price on shares of CRISPR Therapeutics in a report on Thursday, June 26th. Finally, Wall Street Zen raised CRISPR Therapeutics to a "sell" rating in a report on Friday, May 16th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Stock Up 0.3%

The stock has a market capitalization of $5.64 billion, a P/E ratio of -14.45 and a beta of 1.82. The firm has a fifty day moving average price of $44.67 and a two-hundred day moving average price of $41.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. During the same period in the prior year, the company posted ($1.43) earnings per share. The company's quarterly revenue was up 71.6% compared to the same quarter last year. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In related news, Director Simeon George acquired 989,812 shares of the business's stock in a transaction on Wednesday, July 16th. The shares were bought at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the acquisition, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Naimish Patel sold 3,932 shares of the company's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider directly owned 6,068 shares in the company, valued at $218,083.92. This represents a 39.32% decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. SFE Investment Counsel boosted its stake in shares of CRISPR Therapeutics by 5.8% during the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock worth $221,000 after acquiring an additional 355 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in CRISPR Therapeutics by 7.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock worth $215,000 after buying an additional 372 shares during the period. Axxcess Wealth Management LLC grew its holdings in shares of CRISPR Therapeutics by 4.0% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company's stock valued at $351,000 after acquiring an additional 393 shares in the last quarter. GF Fund Management CO. LTD. boosted its holdings in shares of CRISPR Therapeutics by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company's stock worth $74,000 after acquiring an additional 394 shares during the period. Finally, Ipswich Investment Management Co. Inc. raised its position in CRISPR Therapeutics by 1.7% during the second quarter. Ipswich Investment Management Co. Inc. now owns 24,968 shares of the company's stock valued at $1,214,000 after purchasing an additional 425 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.